MedicaidPrior AuthMedium impact
Jevtana® (cabazitaxel)
Humana·LA · Oncology, Urology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Louisiana Medicaid has established a new prior authorization policy for Jevtana (cabazitaxel) for hormone-refractory metastatic prostate cancer treatment. The policy requires specific eligibility criteria including previous docetaxel treatment and concurrent corticosteroid use, with several medical exclusions that could prevent approval.
Action Required
Before September 1, 2025: Billing team must update prior authorization protocols for Jevtana (cabazitaxel) for Louisiana Medicaid patients. Providers must verify patients meet all three criteria: hormone-refractory metastatic prostate cancer diagnosis, previous docetaxel treatment, and concurrent corticosteroid use. Check for exclusions including neutrophil count ≤1,500/mm3, hepatic impairment, and concomitant use with abiraterone or enzalutamide. Claims without proper prior authorization will be denied.